Case-Based Roundtable
General Dermatology
Eczema
Chronic Hand Eczema
Alopecia
Aesthetics
Vitiligo
COVID-19
Actinic Keratosis
Precision Medicine and Biologics
Rare Disease
Wound Care
Rosacea
Psoriasis
Psoriatic Arthritis
Atopic Dermatitis
Melasma
NP and PA
Skin Cancer
Hidradenitis Suppurativa
Drug Watch
Pigmentary Disorders
Acne
Pediatric Dermatology
Practice Management
Prurigo Nodularis
Buy-and-Bill

News

Article

February 5, 2024

Derm In The News: January 28-February 3

Author(s):

Keep up with the latest headlines in dermatology from the past week, including the role of the US in hosting more than half of the world's skin cancer-related trials, new AAD guidelines for acne, and more.

Clinical Trials Arena: The US dominates ongoing/planned trials researching skin cancer

Skin cancer, the most common type of cancer in the US, has nearly 5.5 million cases diagnosed annually. Melanoma, the most aggressive form, can spread if not detected early. Ongoing and planned skin cancer trials are predominantly in the US, with 51.2% of skin cancer-related trials. The next country following the US is China, with 18.1% of hosted skin cancer-related trials.

HealthDay: Dermatologists' Group Offer Latest Guidance on Acne

The American Academy of Dermatology (AAD) has updated guidelines for acne treatment, considering a combination of approaches for both teenagers and adults. The 2024 updates include new topical medications and systemic treatments, with 18 evidence-based recommendations. Strong recommendations include the use of benzoyl peroxide creams, retinoid creams, oral antibiotics, and a combination of these. Good practice recommendations involve combining different treatment types for better results, using antibiotics sparingly to avoid resistance, and considering additional treatments for severe cases. Conditional recommendations include hormonal therapies and various creams or pills targeting specific issues. However, certain treatments, like chemical peels, lasers, and light-based devices, lack sufficient evidence, and others, such as broadband light therapy and intense pulsed light, are discouraged.

Read Dermatology Times' coverage of these updated guidelines here.

Patient-Forward Rundown

Top headlines from this week to share with your patient:

National Rosacea Society: National Rosacea Society Launches New Seal Of Acceptance For Skin Care And Cosmetic Products

The National Rosacea Society (NRS) is introducing a Seal of Acceptance for skin care products and cosmetics suitable for individuals with rosacea. The seal, aimed at helping the estimated 16 million Americans with rosacea, signifies products unlikely to cause irritation or flare-ups. Sensitive skin is a common issue for those with rosacea, and the NRS surveys indicate that specific skincare or cosmetic products can trigger symptoms. The seal program, showcased on rosacea.org, features a list of accepted products, including descriptions and links for purchase. The initiative, developed with dermatologist Zoe Diana Draelos, MD, involves clinical testing for safety and low risk of irritation in individuals with rosacea skin, with applications reviewed by an independent panel of dermatologists.

Mirage News: Scientists Discover Small RNAs Speed Up Skin Wound Healing

A study led by the University of Manchester suggests that microRNA-29s, a class of small RNAs, can play a crucial role in restoring normal skin structure instead of producing scars. The research, conducted in mice and humans and published in The American Journal of Pathology, indicates that microRNA-29s could benefit patients with large-area or deep wounds prone to dysfunctional scarring. The study focused on the molecular events during the early stages of wound healing, showing that microRNA-29s target and promote wound healing by regulating skin regeneration and inhibiting the expression of a structural protein of the skin called laminin C2 (LAMC2).

Connexion France: First treatment for skin condition vitiligo to be available in France

France has granted early approval access to the first-ever treatment for vitiligo. Ruxolitinib (Opzelura, Incyte) will be accessible through a "direct access" scheme initiated in 2021 by President Emmanuel Macron, allowing high-priority patients to access medicines before price negotiations are finalized. The direct access system is expected to last up to a year, after which negotiations for the final drug price and access details will be complete.

Have you seen any dermatology headlines this week that we may have missed? Share with us by emailing our team at DTEditor@mmhgroup.com.